Vertex Pharmaceuticals Incorporated vs Teva Pharmaceutical Industries Limited: A Gross Profit Performance Breakdown

Vertex's profit soars, Teva's declines: A decade of change.

__timestampTeva Pharmaceutical Industries LimitedVertex Pharmaceuticals Incorporated
Wednesday, January 1, 201411056000000519428000
Thursday, January 1, 201511356000000906794000
Friday, January 1, 2016118590000001491717000
Sunday, January 1, 2017108250000002213533000
Monday, January 1, 201882960000002638058000
Tuesday, January 1, 201975360000003615063000
Wednesday, January 1, 202077250000005469383000
Friday, January 1, 202175940000006670200000
Saturday, January 1, 202269730000007850400000
Sunday, January 1, 202376460000008607000000
Monday, January 1, 202480640000009489600000
Loading chart...

Unveiling the hidden dimensions of data

Vertex vs. Teva: A Decade of Gross Profit Evolution

In the competitive landscape of pharmaceuticals, Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, Vertex has experienced a remarkable growth, with its gross profit surging by over 1,500%, reaching approximately $8.6 billion in 2023. This growth underscores Vertex's strategic advancements in innovative treatments and market expansion.

Conversely, Teva's gross profit has seen a decline of about 30% during the same period, dropping from its peak in 2016. This decline reflects the challenges Teva faces, including increased competition and pricing pressures in the generic drug market.

This performance breakdown not only highlights the dynamic nature of the pharmaceutical industry but also emphasizes the importance of innovation and strategic positioning in maintaining financial health.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025